---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033504"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T11:03:51.876423+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025

## Summary
- Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.
- Estimated $2.2 million in severance and benefits costs, recognized in Q1 2025.
- President and CSO Jaume Pons will depart in April 2025; eligible for annual salary and 12 months COBRA.
- No replacement named; position eliminated; transition consulting agreement expected.
- Reduction part of pipeline prioritization and cash preservation strategy.

## SEC filing metadata
- accession: 0000950170-25-033504
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/0000950170-25-033504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/alxo-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033504
- JSON: https://secwatch.observer/filing/0000950170-25-033504.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033504.txt

## Key facts
- Executive change
  Jaume Pons departed as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: departed
  - Role: President and Chief Scientific Officer
  source text: the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017025033504/0000950170-25-033504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.